Wednesday, 4 Nov 2009 | Source: The Associated Press
RNA drug developer Alnylam Pharmaceuticals Inc. reported a deeper third-quarter loss on Wednesday, primarily due to increased spending on stock based compensation and legal costs.
Stocks retreated Tuesday after several earnings reports beat expectations but economic numbers missed their targets. The Dow shed more than 50 points, or 0.5 percent, but still held above 10,000. The S&P and Nasdaq each lost about 0.6 percent.
Stocks retreated Tuesday after several earnings reports beat expectations but economic numbers missed their targets. Apple and Caterpillar surged after their earnings blew past forecasts.
Wednesday, 22 Jul 2009 | Source: The New York Times
A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?